1. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR
- Author
-
Puja Singh, Chul Ho Jeong, Jong-Eun Kim, Yong Yeon Cho, Tae Gyu Lim, Charles C. Lee, Ki Won Lee, Joydeb Kumar Kundu, Ann M. Bode, Zigang Dong, H. S. Chen, Mee-Hyun Lee, Nam Hyouck Lee, Young In Chi, Sung Young Lee, Do Young Lim, and Sung Keun Jung
- Subjects
Lung Neoplasms ,Mutation, Missense ,AKT1 ,Mice, Nude ,Apoptosis ,Biochemistry ,chemistry.chemical_compound ,T790M ,Mice ,Chalcones ,Cell Line, Tumor ,Animals ,Humans ,Epidermal growth factor receptor ,Kinase activity ,Extracellular Signal-Regulated MAP Kinases ,Molecular Biology ,Protein kinase B ,neoplasms ,Cell Proliferation ,biology ,Cell growth ,Wild type ,Cell Biology ,respiratory system ,Molecular biology ,Antineoplastic Agents, Phytogenic ,Xenograft Model Antitumor Assays ,respiratory tract diseases ,Tumor Burden ,ErbB Receptors ,HEK293 Cells ,chemistry ,Cancer research ,biology.protein ,NIH 3T3 Cells ,Protein Processing, Post-Translational ,Proto-Oncogene Proteins c-akt ,Isoliquiritigenin ,Protein Binding ,Signal Transduction - Abstract
Non-small-cell lung cancer (NSCLC) is associated with diverse genetic alterations including mutation of epidermal growth factor receptor (EGFR). Isoliquiritigenin (ILQ), a chalcone derivative, possesses anticancer activities. In the present study, we investigated the effects of ILQ on the growth of tyrosine kinase inhibitor (TKI)-sensitive and -resistant NSCLC cells and elucidated its underlying mechanisms. Treatment with ILQ inhibited growth and induced apoptosis in both TKI-sensitive and -resistant NSCLC cells. ILQ-induced apoptosis was associated with the cleavage of caspase-3 and poly-(ADP-ribose)-polymerase, increased expression of Bim, and reduced expression of Bcl-2. In vitro kinase assay results revealed that ILQ inhibited the catalytic activity of both wild type and double mutant (L858R/T790M) EGFR. Treatment with ILQ inhibited the anchorage-independent growth of NIH3T3 cells stably transfected with either wild type or double-mutant EGFR with or without EGF stimulation. ILQ also reduced the phosphorylation of Akt and ERK1/2 in both TKI-sensitive and -resistant NSCLC cells, and attenuated the kinase activity of Akt1 and ERK2 in vitro. ILQ directly interacted with both wild type and double-mutant EGFR in an ATP-competitive manner. A docking model study showed that ILQ formed two hydrogen bonds (Glu-762 and Met-793) with wild type EGFR and three hydrogen bonds (Lys-745, Met-793, and Asp-855) with mutant EGFR. ILQ attenuated the xenograft tumor growth of H1975 cells, which was associated with decreased expression of Ki-67 and diminished phosphorylation of Akt and ERK1/2. Taken together, ILQ suppresses NSCLC cell growth by directly targeting wild type or mutant EGFR.
- Published
- 2014